Tri Locum Partners LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Tri Locum Partners LP reported 28 stock positions worth $482.7 million. Its top holding was Teva Pharmaceutical-SP ADR (TEVA) at 11.1% of the portfolio, followed by Zimmer Biomet (ZBH, 8.1%) and Argenx SE - ADR (ARGX, 7.4%). Compared with Q3 2024, it opened 12 new positions, sold out of 4, added to 7 and reduced 8. The biggest buy was a new position in Zimmer Biomet (ZBH) and the biggest sale an exit from Pfizer (PFE).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001826434
- Portfolio Value
- $482.7M (Q4 2024)
- SEC Filing
- 0001826434-25-000002 ↗ filed Feb 14, 2025
Holdings Value
Holdings 28 stocks · $482.7M
| TEVA Teva Pharmaceutical-SP ADR | 11.06% | 2,423,116 | $53.4M | Reduce -12.1% |
| ZBH Zimmer Biomet Holdings Inc. | 8.07% | 369,004 | $39.0M | New |
| ARGX Argenx SE - ADR | 7.42% | 58,258 | $35.8M | Reduce -6.8% |
| NTRA Natera Inc. | 6.65% | 202,646 | $32.1M | Reduce -36.2% |
| INSP Inspire Medical Systems Inc. | 5.79% | 150,788 | $28.0M | Reduce -0.4% |
| STVN Stevanato Group SPA | 5.06% | 1,121,804 | $24.4M | Reduce -39.9% |
| AXSM Axsome Therapeutics Inc. | 4.38% | 249,769 | $21.1M | Add +172.3% |
| VRNA Verona Pharma Ltd. | 4.37% | 454,201 | $21.1M | Reduce -23.5% |
| AVDL Avadel Pharmaceuticals Ltd. | 4.22% | 1,937,984 | $20.4M | Add +16.7% |
| BMY Bristol-Myers Squibb Co. | 4.16% | 355,366 | $20.1M | New |
| JAZZ Jazz Pharmaceuticals PLC | 4.13% | 161,812 | $19.9M | New |
| IDXX Idexx Laboratories Inc. | 3.85% | 44,972 | $18.6M | New |
| NVO Novo-Nordisk A/S-Spons ADR | 3.74% | 209,984 | $18.1M | Add +212.2% |
| MDGL Madrigal Pharmaceuticals Inc. | 3.03% | 47,472 | $14.6M | Add +9.7% |
| MRUS Merus NV | 3.03% | 347,303 | $14.6M | Add +80.7% |
| UNH Unitedhealth Group Inc. | 2.95% | 28,115 | $14.2M | New |
| JANX Janux Therapeutics Inc. | 2.62% | 236,407 | $12.7M | New |
| LEGN Legend Biotech Corp.-ADR | 2.62% | 388,704 | $12.6M | Add +7.3% |
| CI The Cigna Group | 2.33% | 40,810 | $11.3M | New |
| WGS Genedx Holdings Corp. | 2.03% | 127,567 | $9.8M | New |
| GERN Geron Corp. | 1.81% | 2,472,836 | $8.8M | New |
| EOLS Evolus Inc. | 1.70% | 742,574 | $8.2M | New |
| MIND MEDICINE MINDMED INC | 1.18% | 820,793 | $5.7M | Reduce -50.6% |
| KRRO Korro Bio Inc. | 1.14% | 144,216 | $5.5M | Add +125.3% |
| BHVN Biohaven Ltd. | 1.08% | 140,220 | $5.2M | Reduce -27.4% |
| LIVN Livanova PLC | 0.96% | 99,700 | $4.6M | New |
| PRAX Praxis Precision Medicines I | 0.59% | 37,269 | $2.9M | New |
| FEMY Femasys Inc. | 0.01% | 30,606 | $34K | No change |
Portfolio Sells Q3 2024 → Q4 2024
| PFE Pfizer Inc. | Sold out | 0.00% | −12.01 |
| PCVX Vaxcyte Inc. | Sold out | 0.00% | −7.44 |
| UTHR United Therapeutics Corp. | Sold out | 0.00% | −4.72 |
| STVN Stevanato Group SPA | Reduce -39.9% | 5.06% | −3.89 |
| NTRA Natera Inc. | Reduce -36.2% | 6.65% | −3.01 |
| INSM Insmed Inc. | Sold out | 0.00% | −2.52 |
| INSP Inspire Medical Systems Inc. | Reduce -0.4% | 5.79% | −1.87 |
| BHVN Biohaven Ltd. | Reduce -27.4% | 1.08% | −1.23 |
| MIND MEDICINE MINDMED INC | Reduce -50.6% | 1.18% | −1.08 |
| TEVA Teva Pharmaceutical-SP ADR | Reduce -12.1% | 11.06% | −0.83 |
| ARGX Argenx SE - ADR | Reduce -6.8% | 7.42% | −0.69 |
| VRNA Verona Pharma Ltd. | Reduce -23.5% | 4.37% | +0.28 |
Portfolio Buys Q3 2024 → Q4 2024
| ZBH Zimmer Biomet Holdings Inc. | New | 8.07% | +8.07 |
| BMY Bristol-Myers Squibb Co. | New | 4.16% | +4.16 |
| JAZZ Jazz Pharmaceuticals PLC | New | 4.13% | +4.13 |
| IDXX Idexx Laboratories Inc. | New | 3.85% | +3.85 |
| UNH Unitedhealth Group Inc. | New | 2.95% | +2.95 |
| JANX Janux Therapeutics Inc. | New | 2.62% | +2.62 |
| AXSM Axsome Therapeutics Inc. | Add +172.3% | 4.38% | +2.40 |
| CI The Cigna Group | New | 2.33% | +2.33 |
| WGS Genedx Holdings Corp. | New | 2.03% | +2.03 |
| NVO Novo-Nordisk A/S-Spons ADR | Add +212.2% | 3.74% | +1.82 |
| GERN Geron Corp. | New | 1.81% | +1.81 |
| EOLS Evolus Inc. | New | 1.70% | +1.70 |
| LIVN Livanova PLC | New | 0.96% | +0.96 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +9.7% | 3.03% | +0.83 |
| MRUS Merus NV | Add +80.7% | 3.03% | +0.73 |
| KRRO Korro Bio Inc. | Add +125.3% | 1.14% | +0.62 |
| PRAX Praxis Precision Medicines I | New | 0.59% | +0.59 |
| AVDL Avadel Pharmaceuticals Ltd. | Add +16.7% | 4.22% | −1.00 |
| LEGN Legend Biotech Corp.-ADR | Add +7.3% | 2.62% | −1.61 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 19 | $813.2M | JNJ, VRTX, LLY, ASND, DXCM |
| Q1 2026 | 17 | $712.5M | JNJ, ISRG, TMO, ASND, VRTX |
| Q4 2025 | 15 | $770.1M | JNJ, DHR, LLY, UTHR, ASND |
| Q3 2025 | 18 | $435.1M | JNJ, UTHR, MRK, AXSM, ASND |
| Q2 2025 | 23 | $329.5M | TEVA, MDGL, ALNY, ARGX, ASND |
| Q1 2025 | 22 | $194.9M | CI, MCK, SLNO, TEVA, INSP |
| Q4 2024 | 28 | $482.7M | TEVA, ZBH, ARGX, NTRA, INSP |
| Q3 2024 | 20 | $417.4M | PFE, TEVA, NTRA, STVN, ARGX |
| Q2 2024 | 25 | $395.5M | TEVA, ARGX, ASND, AMGN, NTRA |
| Q1 2024 | 27 | $288.4M | TEVA, AVDL, SILK, NTRA, ASND |